Bayer files US suit accusing Teva of falsely advertising generic Yaz
This article was originally published in Scrip
Executive Summary
Bayer Schering Pharma has filed yet another lawsuit pertaining to Teva Pharmaceutical Industries' recent US launch of a generic version of Yaz (drospirenone plus ethinyl estradiol) – this time accusing Teva of falsely claiming that its formulation and product contains the same product stabiliser as the branded Yaz product, and for infringing a Yaz patent pertaining to this stabiliser.